Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Jack Taylor-Stuart, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Caroline Furness, David Cunningham, Ian Chau, Dima El-Sharkawi, Sunil Iyengar, Emma Nicholson

Blood (2025) 146 (Supplement 1): 7134.

https://doi.org/10.1182/blood-2025-7134

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Blood (2025) 146 (Supplement 1): 112.

https://doi.org/10.1182/blood-2025-112

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Blood (2025) 146 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2025-2369

Published: 2025

Journal Articles

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2025-1565

Published: 2025

Journal Articles

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Lucy Pickard, Li Yuan Chan, Su Li, Michael Potter, Emma Nicholson, Ian Chau, David Cunningham, Juanah Addada, Emily Chernucha, Sunil Iyengar, Dima El-Sharkawi

Blood (2024) 144 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2024-204653

Published: 2024

Journal Articles

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Patricia Lopez Pereira, Ali Bazarbachi, Ambroise Marçais, Maud Ngoya, Irma Khvedelidze, Ben Carpenter, Victoria Potter, Flore Sicre de Fontbrune, Alina Daniela Tanase, Lucy Cook, Francesca Kinsella, Emma Nicholson, Annoek E. C. Broers, Jennifer Clay, Sr., Hélène Labussière-Wallet, Fabio Ciceri, Bertram Glass, Olivier Hermine, Ana Maria Sureda Balari

Blood (2024) 144 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2024-207307

Published: 2024

Journal Articles

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Blood (2024) 144 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2024-199287

Published: 2024

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 600.

https://doi.org/10.1182/blood-2024-198075

Published: 2024

Journal Articles

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Blood (2024) 144 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2024-206032

Published: 2024

Journal Articles

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 464.

https://doi.org/10.1182/blood-2024-202279

Published: 2024

Journal Articles

Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Blood (2024) 144 (Supplement 1): 595.

https://doi.org/10.1182/blood-2024-194713

Published: 2024

Journal Articles

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Blood (2024) 144 (3): 323–333.

https://doi.org/10.1182/blood.2024024173

Published: 2024

Journal Articles

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A. Von Dem Borne, Emma Nicholson, Didier Blaise, Stephen Robinson, Jr., Aleksandr Kulagin, Sr., Claude-Éric Bulabois, Montserrat Rovira, Patrice Chevallier, Édouard Forcade, Jenny Louise Byrne, Jaime Sanz Caballer, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2023-186293

Published: 2023

Journal Articles

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood (2023) 142 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2023-182808

Published: 2023

Journal Articles

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panapoulou, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve O'Reilly, Robin Sanderson, Sridhar Chaganti

Blood (2023) 142 (Supplement 1): 495.

https://doi.org/10.1182/blood-2023-178834

Published: 2023

Journal Articles

Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT

Blood (2023) 142 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2023-174724

Published: 2023

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only